Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center

Biol Blood Marrow Transplant. 2018 Jun;24(6):1135-1141. doi: 10.1016/j.bbmt.2018.02.018. Epub 2018 Mar 1.

Abstract

Two commercial chimeric antigen receptor (CAR) T cell therapies for CD19-expressing B cell malignancies, Kymriah and Yescarta, have recently been approved by the Food and Drug Administration. The administration of CAR T cells is a complex endeavor involving cell manufacture, tracking and shipping of apheresis products, and management of novel and severe toxicities. At Memorial Sloan Kettering Cancer Center, we have identified 8 essential tasks that define the CAR T cell workflow. In this review, we discuss practical aspects of CAR T cell program development, including clinical, administrative, and regulatory challenges for successful implementation.

Keywords: Acute lymphoblastic leukemia; CAR T cells; Cellular therapy; Chimeric antigen receptor; Cytokine release syndrome; Diffuse large B cell lymphoma.

Publication types

  • Review

MeSH terms

  • Antigens, CD19 / therapeutic use
  • Biological Products
  • Cancer Care Facilities / organization & administration*
  • Humans
  • Immunotherapy, Adoptive / methods*
  • Leukemia, B-Cell / therapy
  • Lymphoma, B-Cell / therapy
  • Receptors, Antigen, T-Cell / therapeutic use
  • Receptors, Chimeric Antigen* / therapeutic use
  • Workflow*

Substances

  • Antigens, CD19
  • Biological Products
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen
  • tisagenlecleucel
  • axicabtagene ciloleucel